DALLAS, July 15, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceuticals Inc. (Nasdaq:KERX). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/KERX
KERX has been relatively stable recently. This is evidenced by the width of its Bollinger Bands which are tighter than normal. Additionally, KERX is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold.
Keryx Biopharmaceuticals Inc. (KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. The Company is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. The Company is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes.
Message Board Search for KERX: http://www.boardcentral.com/boards/KERX
In the report, the analyst notes:
"KERX reported a net loss of $4.0 million, or $0.07 per share, in the first quarter of 2010, compared with a net income of $0.5 million, or $0.01 per share, in the comparable quarter of 2009.
"KERX recently announced that KRX-0401 (perifosine) has received orphan drug status from U.S. health regulators for the treatment of neuroblastoma, a type of childhood cancer for which no FDA-approved therapies currently exist. The designation, which is given to drugs used to treat diseases for which there are few or no treatments, provides the drug developer seven years of U.S. marketing exclusivity, upon approval."
To read the entire report visit: http://www.microstockprofit.com/lp/KERX
See what investors are saying about KERX at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.